Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protein synthesis is crucial for cancer cell growth, making translation a key pharmaceutical target.
• Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent RNA helicase, drives cap-dependent translation initiation by unwinding mRNA.
• Current eIF4A inhibitors primarily target ATP binding, but a novel mechanism is sought.

Purpose of the Study:

• To identify and characterize novel inhibitors of eIF4A ATPase activity.
• To explore a new therapeutic strategy targeting eIF4A for cancer treatment.
• To investigate the mechanism of action of a newly discovered eIF4A inhibitor.

Main Methods:

• High-throughput screening for eIF4A ATPase inhibitors.
• Medicinal chemistry optimization to develop compound 28.
• Biochemical assays, cellular studies, molecular docking, and functional assays to elucidate the inhibition mechanism.

Main Results:

• A novel eIF4A inhibitor, compound 28, was developed.
• Compound 28 acts as an RNA-competitive, ATP-uncompetitive inhibitor.
• It binds to a unique pocket in the eIF4A RNA groove, disrupting RNA binding and ATP hydrolysis, leading to decreased Burkitt lymphoma cell viability.

Conclusions:

• Compound 28 inhibits eIF4A through a novel mechanism, distinct from ATP-competitive inhibitors.
• This unique inhibition strategy offers a promising new avenue for targeting oncogenic pathways.
• Targeting eIF4A via this novel mechanism may lead to new cancer therapeutics.